|Bid||354.28 x 800|
|Ask||354.36 x 900|
|Day's Range||348.26 - 355.41|
|52 Week Range||264.39 - 355.41|
|Beta (5Y Monthly)||0.91|
|PE Ratio (TTM)||38.08|
|Earnings Date||Mar 02, 2020 - Mar 08, 2020|
|Forward Dividend & Yield||0.06 (0.02%)|
|Ex-Dividend Date||Jan 20, 2020|
|1y Target Est||343.58|
It seems that the masses and most of the financial media hate hedge funds and what they do, but why is this hatred of hedge funds so prominent? At the end of the day, these asset management firms do not gamble the hard-earned money of the people who are on the edge of poverty. Truth […]
SAN RAMON, Calif., Jan. 07, 2020 -- CooperCompanies (NYSE: COO), announced today that that consistent with the plan approved by its board of directors to pay annual dividends,.
Cooper Cos. (COO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Today, we'll introduce the concept of the P/E ratio for those who are learning about investing. We'll show how you can...
SAN RAMON, Calif., Dec. 19, 2019 -- CooperCompanies (NYSE:COO) today announced that it will hold its next annual meeting of stockholders on Wednesday, March 18, 2020..
SAN RAMON, Calif., Dec. 09, 2019 -- CooperCompanies (NYSE: COO), will present at the J.P. Morgan Healthcare Conference in San Francisco, Calif., on January 14, 2020. Albert G..
While some investors are already well versed in financial metrics (hat tip), this article is for those who would like...
Cooper Cos. (COO) delivered earnings and revenue surprises of 0.92% and 0.91%, respectively, for the quarter ended October 2019. Do the numbers hold clues to what lies ahead for the stock?
SAN RAMON, Calif., Dec. 05, 2019 -- CooperCompanies (NYSE: COO) today announced financial results for the fiscal fourth quarter and full year ended October 31, 2019. Fourth.
The Insider Monkey team has completed processing the quarterly 13F filings for the September quarter submitted by the hedge funds and other money managers included in our extensive database. Most hedge fund investors experienced strong gains on the back of a strong market performance, which certainly propelled them to adjust their equity holdings so as […]
Guidewire's (GWRE) Q1 results are expected to reflect gains from robust adoption of cloud-based InsurancePlatform suite of solutions. Rising expenditure on product enhancements might have been a drag.
Coupa Software's (COUP) Q3 performance is likely to have gained from an expanding customer base, backed by sturdy adoption of Accelerate and virtual cards for POs.
Cooper Cos. (COO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
In a Q&A with Barron’s, the longtime credit investor discusses where to find value in an increasingly expensive market, his firm’s bet on Puerto Rico’s distressed debt, and why he like’s some Argentine debt.
Cooper Cos. (COO) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Cooper Companies' (COO) CVI Unit has receives FDA approval for its MiSight 1 day contact lens, which complements its commitment to eye health innovation.
FDA Approval Offers New Prospects for Parents, Children and Medical Professionals; Will Become the First and Only Product of its Kind Available in the U.S. SAN RAMON, Calif., Nov. 18, 2019 /PRNewswire/ -- CooperVision announced today it has received U.S. Food and Drug Administration (FDA) approval of its innovative MiSight® 1 day contact lens1. The cornerstone of a comprehensive myopia management approach to be offered by CooperVision, this daily wear, single use contact lens is the first and only FDA-approved product1 clinically proven to slow the progression of myopia (nearsightedness or short-sightedness) when initially prescribed for children 8-12 years old*.
Becomes the First and Only FDA Approved Contact Lens of its Kind in the U.S. SAN RAMON, Calif., Nov. 18, 2019 (GLOBE NEWSWIRE) -- CooperCompanies (COO), announced today that CooperVision has received U.S. Food and Drug Administration (FDA) approval of its MiSight® 1 day contact lens1, indicated to slow the progression of myopia (nearsightedness or short-sightedness) when initially prescribed for children 8-12 years old.
Cooper Companies (COO) is gaining traction from expansion in international markets, robust product portfolio across segments and prudent acquisitions. However, forex continues to remain a concern.